Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Primary Research

Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate

Authors: Zheng Chen, Qiong Liang, Jue Wang, Qun-Xiong Huang, Jian-ning Chen, Zi-jin Weng, Chun-kui Shao, Xin Gao, Jun Pang

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Abstract

Background

Primary malignant lymphoma of the prostate (PMLP) is prone to occur in the elderly, and it has no significant correlation with lactate dehydrogenase (LDH) and prostate specific antigen (PSA). Clinical symptoms and imaging data of PMLP remain unspecific, and its prognosis is poor. A previous result showed that collapsin response mediator protein 4 (CRMP4) promotor methylation can be used as a predictor for lymph node metastases in prostate biopsies. However, the relationship between CRMP4 promotor methylation and PMLP has not been studied.

Methods

We investigated the clinicopathological features of PMLP and the significance of CRMP4 methylation in PMLP. The clinical data and diagnosis information of 10 patients with PMLP were retrospectively analyzed. The CRMP4 promotor methylation level in paraffin-embedded tissues of the 10 patients with PMLP were determined and then compared to limited prostate cancer (LPCa) and its negative lymph node tissue [LPCa-LN (−) (10 cases)] and also to metastatic prostate adenocarcinoma (mPCa) and its positive lymph node tissue [mPCa-LN (+) (10 cases)]. Methylation of the CRMP4 promotor in each group was analyzed statistically. A receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of CRMP4 methylation in PMLP.

Results

The average methylation value of CRMP4 in 10 PMLP patients, 20 cases of prostate adenocarcinoma tissue, 10 cases LPCa-LN (−) and 10 cases mPCa-LN (+) were 42.3, 30.6, 6.7 and 20.3%, respectively. A Kruskal–Wallis test showed that the difference of CRMP4 methylation was significant (X2 = 38.0, P < 0.001). An ROC curve analysis found that CRMP4 methylation > 40.9% could diagnose PMLP. This method had 90% sensitivity and 95% specificity under conditions of CRMP4 methylation > 40.9%. The area under the curve (AUC) was 0.957.

Conclusions

Methylation of the CRMP4 gene was significantly increased in PMLP, and it is expected to become a new predictor for PMLP.
Literature
1.
Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83(4):732–8.CrossRefPubMed
2.
Monzen Y, Nakahara M, Nishisaka T. Spontaneous regression of primary malignant lymphoma of the prostate. Case Rep Urol. 2013;2013:363072.PubMedPubMedCentral
3.
Sarris A, Dimopoulos M, Pugh W, Cabanillas F. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol. 1995;153(6):1852–4.CrossRefPubMed
4.
Hu S, Wang Y, Yang L, Yi L, Nian Y. Primary non-Hodgkin’s lymphoma of the prostate with intractable hematuria: a case report and review of the literature. Oncol Lett. 2015;9(3):1187–90.PubMed
5.
Gorgel SN, Sefik E, Olgunelma V, Sahin E, Balci U, Calli AO. Primary non-Hodgkin follicular lymphoma of the prostate: a case report. Turk J Urol. 2014;40(1):57–8.CrossRefPubMedPubMedCentral
6.
Chu PG, Huang Q, Weiss LM. Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am J Surg Pathol. 2005;29(5):693–9.CrossRefPubMed
7.
Ezekwudo DE, Ogunleye F, Gbadamosi B, Blankenship LM, Kinoyan M, Krauss D, Hollander M, Haberichter K, Jaiyesimi I. Primary extranodal diffuse large B-cell lymphoma of the prostate: a case report. Case Rep Oncol. 2017;10(1):199–204.CrossRefPubMedPubMedCentral
8.
Kakkar A, Rajeshwari M, Bhethanabhotla S, Kaur K, Jain D, Gogia A, Ray R, Seth A. Primary diffuse large B-cell lymphoma of the prostate: a report of two cases with diagnostic considerations. J Cancer Res Ther. 2015;11(4):977–9.CrossRefPubMed
9.
Alvarez CA, Rodriguez BI, Perez LA. Primary diffuse large B-cell lymphoma of the prostate in a young patient. Int Braz J Urol. 2006;32(1):64–5.CrossRefPubMed
10.
Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer. 1985;56(12):2932–8.CrossRefPubMed
11.
Tan F, Thiele CJ, Li Z. Collapsin response mediator proteins: potential diagnostic and prognostic biomarkers in cancers (Review). Oncol Lett. 2014;7(5):1333–40.PubMedPubMedCentral
12.
Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, Fang YQ, Liu XP, Pu XY, He D, et al. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010;29(32):4555–66.CrossRefPubMed
13.
Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Futterer JJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9(9):850–6.CrossRefPubMed
14.
Miyahara T, Oyabul Y, Hayashi T, Shimizu S, Tanaka H, Matsuoka K. A case of malignant lymphoma of the prostate. Nihon Hinyokika Gakkai zasshi Jpn J Urol. 2005;96(6):644–6.
15.
Wang C, Jiang P, Li J. Primary lymphomas of the prostate: two case reports and a review of the literature. Contemp Oncol. 2012;16(5):456–9.
16.
Noguchi W, Inoue Y, Fukushima M. A case of prostatic abscess with malignant lymphoma involving the prostate. Case Rep Urol. 2014;2014:965823.PubMedPubMedCentral
17.
Csomor J, Kaszas I, Kollar B, Pajor L, Egyhazi Z, Fekete S, Egyed M, Timar B. Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma. Pathol Oncol Res POR. 2008;14(3):281–4.CrossRefPubMed
18.
Boe S, Nielsen H, Ryttov N. Burkitt’s lymphoma mimicking prostatitis. J Urol. 1981;125(6):891–2.CrossRefPubMed
19.
Said JW. Aggressive B-cell lymphomas: how many categories do we need? Mod Pathol. 2013;26(01):S42–56.CrossRefPubMed
20.
Muringampurath-John D, Jaye DL, Flowers CR, Saxe D, Chen Z, Lechowicz MJ, Weisenburger DD, Bast M, Arellano ML, Bernal-Mizrachi L, et al. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol. 2012;158(5):608–14.CrossRefPubMed
21.
Gao X, Li LY, Rassler J, Pang J, Chen MK, Liu WP, Chen Z, Ren SC, Zhou FJ, Xie KJ et al. Prospective study of CRMP4 promoter methylation in prostate biopsies as a predictor for lymph node metastases. J Natl Cancer Inst. 2017;109(6):djw282.
Metadata
Title
Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate
Authors
Zheng Chen
Qiong Liang
Jue Wang
Qun-Xiong Huang
Jian-ning Chen
Zi-jin Weng
Chun-kui Shao
Xin Gao
Jun Pang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0484-9

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue

Correction

Correction to: Effect of long non-coding RNA Gas5 on proliferation, migration, invasion and apoptosis of colorectal cancer HT-29 cell line

Primary Research

RRS1 gene expression involved in the progression of papillary thyroid carcinoma

Primary research

Long noncoding RNA ROR promotes breast cancer by regulating the TGF-β pathway

Primary research

ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R

Primary Research

Transcription factor E2F3a regulates CASP8AP2 transcription and enhances sensitivity to chemotherapeutic drugs in acute lymphoblastic leukemia

Primary research

LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits